Monitoring of Piperacillin-Tazobactam and Meropenem Plasmatic Levels in Critical Patients

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Status: Unknown

Conditions: Septic Shock; Sepsis

Treatments: Drug: Piperacillin/tazobactam or Meropenem

Study type: Observational

Funder types: Other

Identifiers

NCT04257838

FIS-MER-2019-01

Details and patient eligibility

About

The aim of this study is to establish the Piperacillin-Tazobactam and Meropenem Plasmatic Levels to know if it´s necessary to make some adjustment in the recommended dose regimen.

Enrollment: 200 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients above 18 years old.
• Hospitalized in the Intense Care Unit.
• Patients treated with Piperacillin-Tazobactam or Meropenem.
• Septic shock.
• Renal hyper clearance.
• Gram-negative bacillary bacteremia.
• Continuous renal replacement technique.
• ECMO.
• Obesity (BMI> 40).

Exclusion criteria

• Patients under 18 years old.
• Pregnant women.

Trial design

200 participants in 1 patient group

Piperacillin-Tazobactam or Meropenem Cohort

Description:

Patients hospitalized for sepsis or septic shock that are treated with Piperacillin-Tazobactam or Meropenem and meet all the inclusion criteria and none of the exclusion criteria.

Treatment:

Drug: Piperacillin/tazobactam or Meropenem